A new treatment strategy for acute liver failure

Kazuhiro Kotoh, Masaki Kato, Motoyuki Kohjima, Makoto Nakamuta, Munechika Enjoji

Research output: Contribution to journalEditorial

9 Citations (Scopus)

Abstract

Acute liver failure (ALF) is a syndrome defined by coa gulopathy and encephalopathy and no effective treatments have been established, except for liver transplantation. However, considering the limited supply of donors, we should endeavor to prevent the progression of this syndrome in its early stage to improve the prognosis of patients with ALF. Recently, several authors have reported that over-activation of intrahepatic macrophages plays an important role in the progression of ALF and we have developed a new treatment method, transcatheter arterial steroid injection therapy (TASIT), to suppress macrophage activation. We have now used TASIT for 5 years and have found that TASIT is effective for patients with over-activation of macrophages in the liver but not for those with lesser activation of macrophages. Therefore, to identify the most appropriate patients for TASIT, we tried to categorize patients with ALF or acute liver injury according to markers for the degree of intrahepatic macrophage activation. This approach was helpful to select the appropriate treatment including liver transplantation. We believe that it is essential to analyze disease progression in each patient before selecting the most appropriate treatment.

Original languageEnglish
Pages (from-to)395-400
Number of pages6
JournalWorld Journal of Hepatology
Volume2
Issue number11
DOIs
Publication statusPublished - Dec 1 2010

Fingerprint

Acute Liver Failure
Macrophage Activation
Steroids
Injections
Therapeutics
Liver Transplantation
Liver
Brain Diseases
Disease Progression
Tissue Donors
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

A new treatment strategy for acute liver failure. / Kotoh, Kazuhiro; Kato, Masaki; Kohjima, Motoyuki; Nakamuta, Makoto; Enjoji, Munechika.

In: World Journal of Hepatology, Vol. 2, No. 11, 01.12.2010, p. 395-400.

Research output: Contribution to journalEditorial

Kotoh, Kazuhiro ; Kato, Masaki ; Kohjima, Motoyuki ; Nakamuta, Makoto ; Enjoji, Munechika. / A new treatment strategy for acute liver failure. In: World Journal of Hepatology. 2010 ; Vol. 2, No. 11. pp. 395-400.
@article{cdff71aa8c894ac8ac04b90461e9e613,
title = "A new treatment strategy for acute liver failure",
abstract = "Acute liver failure (ALF) is a syndrome defined by coa gulopathy and encephalopathy and no effective treatments have been established, except for liver transplantation. However, considering the limited supply of donors, we should endeavor to prevent the progression of this syndrome in its early stage to improve the prognosis of patients with ALF. Recently, several authors have reported that over-activation of intrahepatic macrophages plays an important role in the progression of ALF and we have developed a new treatment method, transcatheter arterial steroid injection therapy (TASIT), to suppress macrophage activation. We have now used TASIT for 5 years and have found that TASIT is effective for patients with over-activation of macrophages in the liver but not for those with lesser activation of macrophages. Therefore, to identify the most appropriate patients for TASIT, we tried to categorize patients with ALF or acute liver injury according to markers for the degree of intrahepatic macrophage activation. This approach was helpful to select the appropriate treatment including liver transplantation. We believe that it is essential to analyze disease progression in each patient before selecting the most appropriate treatment.",
author = "Kazuhiro Kotoh and Masaki Kato and Motoyuki Kohjima and Makoto Nakamuta and Munechika Enjoji",
year = "2010",
month = "12",
day = "1",
doi = "10.4254/wjh.v2.i11.395",
language = "English",
volume = "2",
pages = "395--400",
journal = "World Journal of Hepatology",
issn = "1948-5182",
publisher = "Baishideng Publishing Group",
number = "11",

}

TY - JOUR

T1 - A new treatment strategy for acute liver failure

AU - Kotoh, Kazuhiro

AU - Kato, Masaki

AU - Kohjima, Motoyuki

AU - Nakamuta, Makoto

AU - Enjoji, Munechika

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Acute liver failure (ALF) is a syndrome defined by coa gulopathy and encephalopathy and no effective treatments have been established, except for liver transplantation. However, considering the limited supply of donors, we should endeavor to prevent the progression of this syndrome in its early stage to improve the prognosis of patients with ALF. Recently, several authors have reported that over-activation of intrahepatic macrophages plays an important role in the progression of ALF and we have developed a new treatment method, transcatheter arterial steroid injection therapy (TASIT), to suppress macrophage activation. We have now used TASIT for 5 years and have found that TASIT is effective for patients with over-activation of macrophages in the liver but not for those with lesser activation of macrophages. Therefore, to identify the most appropriate patients for TASIT, we tried to categorize patients with ALF or acute liver injury according to markers for the degree of intrahepatic macrophage activation. This approach was helpful to select the appropriate treatment including liver transplantation. We believe that it is essential to analyze disease progression in each patient before selecting the most appropriate treatment.

AB - Acute liver failure (ALF) is a syndrome defined by coa gulopathy and encephalopathy and no effective treatments have been established, except for liver transplantation. However, considering the limited supply of donors, we should endeavor to prevent the progression of this syndrome in its early stage to improve the prognosis of patients with ALF. Recently, several authors have reported that over-activation of intrahepatic macrophages plays an important role in the progression of ALF and we have developed a new treatment method, transcatheter arterial steroid injection therapy (TASIT), to suppress macrophage activation. We have now used TASIT for 5 years and have found that TASIT is effective for patients with over-activation of macrophages in the liver but not for those with lesser activation of macrophages. Therefore, to identify the most appropriate patients for TASIT, we tried to categorize patients with ALF or acute liver injury according to markers for the degree of intrahepatic macrophage activation. This approach was helpful to select the appropriate treatment including liver transplantation. We believe that it is essential to analyze disease progression in each patient before selecting the most appropriate treatment.

UR - http://www.scopus.com/inward/record.url?scp=83155190052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83155190052&partnerID=8YFLogxK

U2 - 10.4254/wjh.v2.i11.395

DO - 10.4254/wjh.v2.i11.395

M3 - Editorial

AN - SCOPUS:83155190052

VL - 2

SP - 395

EP - 400

JO - World Journal of Hepatology

JF - World Journal of Hepatology

SN - 1948-5182

IS - 11

ER -